Dignitana AB, world leader in medical scalp cooling technology, announced today that the company has signed a contract with Atrium Health to provide the DigniCap Delta model of The DigniCap® Scalp Cooling System to Atrium Health’s Levine Cancer Institute sites. Dignitana’s advanced and redesigned scalp cooling device received FDA clearance for use on 26 June 2019. Atrium Health is a leading healthcare provider in the U.S. and the first new customer with multiple locations to contract with Dignitana for the DigniCap Delta device.
“DigniCap Delta provides state-of-the-art scalp cooling and we are seeing growing demand for this new technology,” says William Cronin, Chief Executive Officer of Dignitana AB. “As we work to move modern cancer care forward, we are proud to add Atrium Health to the list of progressive healthcare organizations that offer cancer patients this important therapy option.”
Headquartered in Charlotte, North Carolina, Atrium Health has a network of more than 50 hospitals, including more than 25 locations of Levine Cancer Institute across the Carolinas. The first DigniCap Delta will be installed at the flagship Levine Cancer Institute facility in Charlotte in September, after which time Dignitana will work closely with administration to provide scalp cooling at the remaining infusion centers based on market demand.
Following FDA clearance in June, DigniCap Delta is now available to medical centers in the United States. European installations of DigniCap Delta began last month after the device received CE Marking in March 2019. The previous DigniCap device, C3, is already in use in 30 states in the U.S. and in 37 markets globally.
DigniCap Delta uses solid state cooling for precise temperature control in an advanced and redesigned model of the 2015 FDA cleared DigniCap Scalp Cooling System. The new device delivers significant improvements over other scalp cooling systems on the market:
- Single patient use
New cap system provides each patient with a flexible Cooling Wrap and an adjustable Thermal Cap designed to optimize scalp cooling outcomes and minimize clinic storage needs.
- Smaller size
Streamlined profile is 54 percent smaller than the previous unit.
- Reduced nursing time
Intuitive interface means up to 80 percent reduction in nursing time per patient infusion versus the existing device.
Lund, Sweden 30 July 2019
For More Information Contact
Caren Browning, King + Company, firstname.lastname@example.org +1 212-561-7464
Anna Westesson, Anna Westesson PR & Consulting AB, email@example.com +46 708-82 82 09
Melissa Bourestom, Dignitana AB firstname.lastname@example.org +1 469-518-5031
About Dignitana AB (publ)
Dignitana AB is the world leader in clinically superior scalp cooling technology. The company produces The DigniCap® Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss DigniCap Delta during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and patient comfort. Hailed internationally as a life-changing medical advancement for cancer patients, The DigniCap Scalp Cooling System was invented in 1999 by a Swedish Oncology nurse and has been available in Europe since 2001. Dignitana AB is listed on Nasdaq First North Stockholm in Sweden with headquarters in Lund, Sweden and operations based in Dallas, Texas in the United States. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Learn more at www.dignitana.se and www.dignicap.com. Erik Penser Bank AB, Certified Adviser, +46 (0) 8 463 83 00 email@example.com www.penser.se
Video: DigniCap Delta Introduction https://youtu.be/GiCVZ20ViOU